876043--1/16/2007--MEDWAVE

related topics

{stock, price, share}

{product, candidate, development}

{customer, product, revenue}

{acquisition, growth, future}

{product, market, service}

{stock, price, operating}

{control, financial, internal}

{product, liability, claim}

{personnel, key, retain}

{property, intellectual, protect}

{operation, international, foreign}

{financial, litigation, operation}

{system, service, information}

Our products may not perform adequately or be placed properly. We must continue to evaluate the design of our products. We may not have adequate intellectual property protection. Our technology may become obsolete. We have a new management team. We recently decided to relocate our corporate office which may adversely impact our business. We may not be able to manage growth. We have limited manufacturing experience and capability. We have only one manufacturing facility, the loss of which would harm our revenues and damage our customer relations. Our sources of supply are concentrated in a single geographic area. We must maintain and develop strategic relationships with third parties to increase market penetration of our product lines. Our international sales expose us to risks. We may not continue to receive necessary FDA clearances or approvals. We may not receive approvals by foreign regulators that are necessary for international sales. We may be subject to product liability claims and our products may require modification if patients have complications that are potentially attributable to our products. We have a history of losses and may experience continued losses. We may need additional capital, which may be unavailable. A continued low stock price, the failure to maintain a minimum of $2.5 million of stockholders equity or our inability to comply with other applicable requirements could result in our being de-listed from the NASDAQ Capital Market and subject us to regulations that could reduce our ability to raise funds. Our common stock is subject to price volatility. Common stock which is available for immediate resale may depress our market price. Our common stock is thinly traded, so a shareholder may be unable to sell at or near ask price or at all if you need to liquidate your shares. If securities or industry analysts do not publish research or reports about our business, or if they change their recommendations regarding our stock adversely, our stock price and trading volume could decline. We do not intend to pay dividends in the foreseeable future.

Full 10-K form ▸

876043--1/16/2007--MEDWAVE_INC